000303643 001__ 303643
000303643 005__ 20250828084623.0
000303643 0247_ $$2doi$$a10.3238/arztebl.m2025.0099
000303643 0247_ $$2pmid$$apmid:40536418
000303643 0247_ $$2altmetric$$aaltmetric:179647602
000303643 037__ $$aDKFZ-2025-01707
000303643 041__ $$aEnglish
000303643 082__ $$a610
000303643 1001_ $$0P:(DE-He78)f84639cbc39bc20ecda8d00e6de97578$$aAlbers, Peter$$b0$$eFirst author$$udkfz
000303643 245__ $$aThe Early Detection, Diagnostic Evaluation, and Local Treatment of Prostate Cancer: A Paradigm Shift.
000303643 260__ $$aKöln$$bDt. Ärzte-Verl.$$c2025
000303643 3367_ $$2DRIVER$$aarticle
000303643 3367_ $$2DataCite$$aOutput Types/Journal article
000303643 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1756363535_18473$$xReview Article
000303643 3367_ $$2BibTeX$$aARTICLE
000303643 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000303643 3367_ $$00$$2EndNote$$aJournal Article
000303643 500__ $$a#EA:C130# / 2025 Jul 5;122(15):420-426
000303643 520__ $$aApproximately 75 000 men receive a diagnosis of prostate cancer in Germany each year. New data on the early detection, diagnostic evaluation, and treatment of prostate cancer provide the basis for a paradigm shift in the management of locally confined prostate cancer.This narrative review is based on the systematic literature search that was carried out for the 2025 update of the German clinical practice guideline on prostate cancer.Risk-adapted early detection is now recommended. This involves the measurement of a baseline PSA value at age 45 whose magnitude determines the interval of follow-up testing: once every 5 years for baseline values below 1.5 ng/mL, and once every two years for baseline values between 1.5 and 3 ng/mL. Patients with PSA levels above 3 ng/mL should undergo a repeat PSA test and, if these levels are confirmed, receive a urological risk assessment including prostatic volume, family history, and past medical history. High risk patients should undergo magnetic resonance imaging (MRI) and, if necessary, prostate biopsy. This new PSA-MRI algorithm increases accuracy in detecting clinically significant prostate cancers, enabling the previously recommended annual testing and digital rectal examination to be avoided. Another novelty is that the indication for an active surveillance strategy for men with low-risk prostate cancer has been expanded to ISUP grade group 1 and 2 cancers with favorable risk.The need for high-quality diagnostic testing, including MRI, with broad geographic coverage will be a major challenge to the health care system, especially with regard to accessibility. Patients can be expected to benefit greatly from the new PSA-MRI algorithm, as it eliminates unnecessary diagnostic testing and treatment while enabling necessary treatment to be initiated earlier and therefore with fewer side effects.
000303643 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000303643 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000303643 7001_ $$aFraniel, Tobias$$b1
000303643 7001_ $$aKötter, Thomas$$b2
000303643 7001_ $$aKristiansen, Glen$$b3
000303643 7001_ $$0P:(DE-HGF)0$$aHerrmann, Ken$$b4
000303643 7001_ $$aWiegel, Thomas$$b5
000303643 773__ $$0PERI:(DE-600)2406159-1$$a10.3238/arztebl.m2025.0099$$gno. Forthcoming$$n15$$p420-426$$tDeutsches Ärzteblatt international$$v122$$x1866-0452$$y2025
000303643 909CO $$ooai:inrepo02.dkfz.de:303643$$pVDB
000303643 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f84639cbc39bc20ecda8d00e6de97578$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000303643 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000303643 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000303643 9141_ $$y2025
000303643 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bDTSCH ARZTEBL INT : 2022$$d2025-01-07
000303643 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-07
000303643 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-07
000303643 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-07
000303643 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-07
000303643 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-07
000303643 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-07
000303643 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bDTSCH ARZTEBL INT : 2022$$d2025-01-07
000303643 9201_ $$0I:(DE-He78)C130-20160331$$kC130$$lPersonalisierte Früherkennung des Prostatakarzinoms$$x0
000303643 9201_ $$0I:(DE-He78)ED01-20160331$$kED01$$lDKTK Koordinierungsstelle Essen/Düsseldorf$$x1
000303643 9200_ $$0I:(DE-He78)C130-20160331$$kC130$$lPersonalisierte Früherkennung des Prostatakarzinoms$$x0
000303643 980__ $$ajournal
000303643 980__ $$aVDB
000303643 980__ $$aI:(DE-He78)C130-20160331
000303643 980__ $$aI:(DE-He78)ED01-20160331
000303643 980__ $$aUNRESTRICTED